Methods
T2D
SMARTEST is a nationwide study with more than 30 study sites. The participants are randomized 1:1 to dapagliflozin or metformin and are then followed in regular care. Periodical withdrawals from national registers, including NDR, are made for endpoint collections. Adults with T2D according to WHO criteria with less than 4 years duration and BMI 18.5–45 kg/mThis sub study to SMARTEST was conducted in the Uppsala, Örebro and Sörmland counties. For participants included in the SMARTEST study and residing within the respective county, data was manually extracted from EHRs between 7 April 2021 and 30 March 2022 and compared to data extracted from the NDR on 8 June 2022. Participants were generally included in the order of inclusion in the SMARTEST study in each county, with some exceptions due to work distribution among the study personnel. The participants had consented to data collection from EHRs when signing the written informed consent to the SMARTEST study, which has received approval from the Swedish Ethical Review Authority (DNR 2019-01747).